WINDTREE THERAPEUTICS INC /DE/ Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
WINDTREE THERAPEUTICS INC /DE/ (WINT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 112.00% for the 12-month period ending 2023-12-31, per its 10-K filed 2025-04-15.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2025-04-15
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2023-03-31 was 106.00%, a 0.00% change year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2022-03-31 was 106.00%, a 0.95% increase year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2021-03-31 was 105.00%.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2019-03-31 was 96.00%, a 21.52% increase year-over-year.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2023 was 112.00%, a 5.66% increase from fiscal 2022.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2022 was 106.00%, a 1.92% increase from fiscal 2021.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2021 was 104.00%, a 0.97% increase from fiscal 2020.
- WINDTREE THERAPEUTICS INC /DE/ share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2020 was 103.00%, a 8.42% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 12 month |
|---|---|---|---|---|
| 2023-12-31 | 112.00% 10-K · filed 2025-04-15 | |||
| 2023-09-30 | 112.00% 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | 106.00% 10-Q · filed 2023-08-07 | |||
| 2023-03-31 | 106.00% 10-Q · filed 2023-05-15 | |||
| 2022-12-31 | 106.00% 10-K · filed 2024-04-16 | |||
| 2022-09-30 | 106.00% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 106.00% 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | 106.00% 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | 104.00% 10-K · filed 2023-03-31 | |||
| 2021-09-30 | 104.00% 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 105.00% 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | 105.00% 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | 103.00% 10-K · filed 2022-03-31 | |||
| 2020-09-30 | 103.00% 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | 98.00% 10-Q · filed 2021-08-05 | |||
| 2019-12-31 | 95.00% 10-K · filed 2021-03-29 | |||
| 2019-09-30 | 95.00% 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | 95.00% 10-Q · filed 2020-08-14 | |||
| 2019-03-31 | 96.00% 10-Q · filed 2019-05-20 | |||
| 2018-12-31 | 93.00% 10-K · filed 2020-04-03 | |||
| 2018-03-31 | 79.00% 10-Q · filed 2018-05-21 | |||
| 2017-12-31 | 79.00% 10-K/A · filed 2019-04-23 | |||
| 2017-09-30 | 79.00% 10-Q · filed 2018-11-14 | |||
| 2017-06-30 | 79.00% 10-Q · filed 2018-08-14 | |||
| 2017-03-31 | 79.00% 10-Q · filed 2017-05-15 | |||
| 2016-12-31 | 78.00% 10-K · filed 2018-04-17 | |||
| 2016-09-30 | 78.00% 10-Q · filed 2017-11-14 | |||
| 2016-06-30 | 79.00% 10-Q · filed 2017-08-21 | |||
| 2016-03-31 | 79.00% 10-Q · filed 2017-05-15 | |||
| 2015-12-31 | 83.00% 10-K · filed 2017-03-31 | |||
| 2015-09-30 | 83.00% 10-Q · filed 2016-11-14 | |||
| 2015-06-30 | 83.00% 10-Q · filed 2016-08-10 | |||
| 2015-03-31 | 83.00% 10-Q · filed 2016-05-12 | |||
| 2014-12-31 | 100.00% 10-K · filed 2016-03-29 | |||
| 2014-09-30 | 100.00% 10-Q · filed 2015-11-05 | |||
| 2014-06-30 | 100.00% 10-Q · filed 2015-08-10 | |||
| 2014-03-31 | 100.00% 10-Q · filed 2015-05-11 | |||
| 2013-12-31 | 109.00% 10-K · filed 2015-03-16 | |||
| 2013-09-30 | 110.00% 10-Q · filed 2014-11-07 | |||
| 2013-06-30 | 110.00% 10-Q · filed 2013-08-08 | 110.00% 10-Q · filed 2014-08-07 | ||
| 2013-03-31 | 110.00% 10-Q · filed 2014-05-12 | |||
| 2012-12-31 | 111.00% 10-K · filed 2015-03-16 | |||
| 2012-09-30 | 110.00% 10-Q · filed 2013-11-12 | |||
| 2012-06-30 | 110.00% 10-Q · filed 2013-08-08 | 110.00% 10-Q · filed 2012-08-14 | ||
| 2012-03-31 | 113.00% 10-Q · filed 2013-05-07 | |||
| 2011-12-31 | 113.00% 10-K · filed 2014-03-17 | |||
| 2011-09-30 | 112.00% 10-Q · filed 2012-11-14 | |||
| 2011-06-30 | 112.00% 10-Q · filed 2012-08-14 | |||
| 2010-12-31 | 112.00% 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |